- Home
- STG vs SLS Comparison
STG vs SLS Comparison
Compare STG & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- SLS
- Stock Information
- Founded
- STG 2003
- SLS 2012
- Country
- STG China
- SLS United States
- Employees
- STG N/A
- SLS N/A
- Industry
- STG Other Consumer Services
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- SLS Health Care
- Exchange
- STG Nasdaq
- SLS Nasdaq
- Market Cap
- STG 83.8M
- SLS 75.3M
- IPO Year
- STG 2018
- SLS N/A
- Fundamental
- Price
- STG $6.45
- SLS $0.87
- Analyst Decision
- STG
- SLS
- Analyst Count
- STG 0
- SLS 0
- Target Price
- STG N/A
- SLS N/A
- AVG Volume (30 Days)
- STG 4.7K
- SLS 1.6M
- Earning Date
- STG 11-22-2024
- SLS 11-13-2024
- Dividend Yield
- STG N/A
- SLS N/A
- EPS Growth
- STG N/A
- SLS N/A
- EPS
- STG 4.57
- SLS N/A
- Revenue
- STG $292,030,936.00
- SLS N/A
- Revenue This Year
- STG N/A
- SLS N/A
- Revenue Next Year
- STG N/A
- SLS N/A
- P/E Ratio
- STG $1.46
- SLS N/A
- Revenue Growth
- STG N/A
- SLS N/A
- 52 Week Low
- STG $4.25
- SLS $0.50
- 52 Week High
- STG $12.55
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- STG 49.04
- SLS 30.01
- Support Level
- STG $6.10
- SLS $0.86
- Resistance Level
- STG $6.68
- SLS $0.98
- Average True Range (ATR)
- STG 0.30
- SLS 0.11
- MACD
- STG 0.04
- SLS -0.02
- Stochastic Oscillator
- STG 63.95
- SLS 21.74
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.